Antibody Slows Beta-Cell Loss Early in Type 1 Diabetes
A course of teplizumab (Tzield) may help preserve beta-cells when given early after a type 1 diabetes (T1D) diagnosis, similar to the anti-CD3 antibody’s delay on progression from preclinical disease, the randomized PROTECT trial showed. Two 12-day courses of the drug resulted in 59.3% less loss of beta-cell function, with higher stimulated C-peptide levels at […]